In the context of cancer, SLFN11 helps sensitize cancer cells to DNA-damaging agents like topoisomerase I and II inhibitors (such as irinotecan and etoposide, respectively), DNA synthesis inhibitors (e.g., gemcitabine), and DNA cross-linkers and alkylating agents (e.g., cisplatin) [8,14]. Here, SLFN11 is linked to cancer.